SCHEDULE: Vanguard Amends Anavex Life Sciences Ownership Report

The Vanguard Group filed an amendment to its Schedule 13G for Anavex Life Sciences Corp., reporting zero beneficial ownership following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to its Schedule 13G for Anavex Life Sciences Corp. Common Stock.
• The filing reports that The Vanguard Group now beneficially owns 0% of Anavex Life Sciences Corp. common stock, with 0 shares having sole or shared voting and dispositive power.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• These subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily an administrative update regarding The Vanguard Group's internal reporting structure rather than a reflection of Anavex Life Sciences Corp.'s performance or prospects.

Future Outlook

The filing indicates that The Vanguard Group's subsidiaries and/or business divisions will continue to pursue the same investment strategies and will report their beneficial ownership separately in the future.

Industry Context

StockSavvy.ai notes that such internal realignments by large asset managers like Vanguard are administrative in nature and typically do not reflect a change in investment strategy towards the underlying issuer, Anavex Life Sciences Corp., but rather a change in how beneficial ownership is reported across their various entities.

Stakeholder Impact

• Minimal direct impact on Anavex Life Sciences Corp. shareholders, as the underlying investment strategies of Vanguard's entities remain the same.
• Primarily affects how Vanguard's ownership is aggregated and reported to regulatory bodies.

Next Steps

• Vanguard's subsidiaries and/or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in future filings.

Key Dates

Keywords

Anavex Life Sciences, Vanguard Group, Schedule 13G, beneficial ownership, SEC filing, common stock, institutional ownership, investment adviser